Current Cancer Drug Targets

A.K. Chakraborty received his Ph.D. (Melanogenesis) from the University of Calcutta, India. Currently, he is an Inventor at Cancer Drug Development, Allexcel, Inc., Shelton, CT and a Research Scientist at the Dept. of Dermatology/Oncology, Yale University School of Medicine, New Haven, CT. He has published 81 articles and 9 book chapters in well-reputed journals.

Dr. B. Chumworathayi is currently as an Associate Dean for Human Resources, at the Faculty of Medicine, Khon Kaen University, from 2015 to 2017. He received his Ph.D degree in Clinical Science, from Khon Kaen University, in 2009. His research interests are Medicine (General), Surgery (Pelvic), Family Medicine, Obstetrics (Operative), Gynecology (STDs), Gynecologic Oncology, Preventive Medicine, Epidemiology (Clinical), Clinical Science (Research Methodology).

EMT is an early step leading to solid tumor progression and is implicated in tumor growth, invasion, metastasis and resistance to therapy. Our research is to combat against cancer from the aspects of EMT involved with genetic and epigenetic events.

Dr. Mohammed Mansour is an MRC Postdoctoral Research Scientist interested in deciphering the molecular mechanisms of stem cell fate determination in mouse mammary gland. He joined the School of Biological Sciences at the University of Southampton in March 2019. Dr. Mansour’s research is tailored to study the dynamics of spindle orientation during cell division and how this dictate the fate decisions in mammary stem cells.